Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
K Ghoreschi, A Balato, C Enerbäck, R Sabat - The Lancet, 2021 - thelancet.com
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …
Pathophysiology, clinical presentation, and treatment of psoriasis: a review
AW Armstrong, C Read - Jama, 2020 - jamanetwork.com
Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
R Bissonnette, A Pinter, LK Ferris… - … England Journal of …, 2024 - Mass Medical Soc
Background The use of monoclonal antibodies has changed the treatment of several
immune-mediated inflammatory diseases, including psoriasis. However, these large …
immune-mediated inflammatory diseases, including psoriasis. However, these large …
Challenges and future trends in the treatment of psoriasis
HJ Lee, M Kim - International Journal of Molecular Sciences, 2023 - mdpi.com
Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical
therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate …
therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
E Sbidian, A Chaimani, R Guelimi… - Cochrane Database …, 2023 - cochranelibrary.com
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …
manifestations, or both, and it has a major impact on quality of life. Although there is …
Disease modification in inflammatory skin disorders: opportunities and challenges
T Bieber - Nature Reviews Drug Discovery, 2023 - nature.com
Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
Biologics‐loaded photothermally dissolvable hyaluronic acid microneedle patch for psoriasis treatment
Emerging biologics, such as monoclonal antibodies (mAbs), are the most promising
treatment for psoriasis, while their effective delivery to the local inflammatory area of the skin …
treatment for psoriasis, while their effective delivery to the local inflammatory area of the skin …
Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art review
Psoriasis is a chronic, autoimmune, and non-communicable skin disease with a worldwide
prevalence rate of 2–3%, creating an economic burden on global health. Some significant …
prevalence rate of 2–3%, creating an economic burden on global health. Some significant …
[HTML][HTML] From empirical to pathogenesis-based treatments for psoriasis
PCM van de Kerkhof - Journal of Investigative Dermatology, 2022 - Elsevier
Since the foundation of the European Society for Dermatological Research, pathogenesis of
psoriasis has been studied by many research groups, focusing on various compartments of …
psoriasis has been studied by many research groups, focusing on various compartments of …
Risankizumab treatment in psoriasis patients who failed anti‐IL17: a 52‐week real‐life study
M Megna, L Potestio, A Ruggiero… - Dermatologic …, 2022 - Wiley Online Library
Recent knowledge on the key role of interleukin (IL) 23/17 axis in psoriasis pathogenesis,
led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin …
led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin …